Cargando…

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

BACKGROUND: Dimethyl fumarate (BG-12, Tecfidera®) is a new oral drug approved by FDA and EMA in March 2013 for relapsing – remitting multiple sclerosis (RRMS). The drug was much anticipated because of its possible superiority over currently available medications: fingolimod and teriflunomide as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawalec, Paweł, Mikrut, Alicja, Wiśniewska, Natalia, Pilc, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023455/ https://www.ncbi.nlm.nih.gov/pubmed/24851089 http://dx.doi.org/10.2174/1570159X12666140115214801

Ejemplares similares

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kawalec, Paweł, et al.
Publicado: (2013)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Dimethyl Fumarate-Induced Takotsubo Cardiomyopathy in a Patient With Relapsing-Remitting Multiple Sclerosis
por: Srichawla, Bahadar S
Publicado: (2022)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
por: Kania, Karolina, et al.
Publicado: (2022)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2014)

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
por: Eriksson, Irene, et al.
Publicado: (2017)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Carlström, Karl E., et al.
Publicado: (2019)

Advances in the management of relapsing–remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
por: Nielsen, A Scott
Publicado: (2015)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
por: Alroughani, Raed, et al.
Publicado: (2021)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
por: Ginestal, Ricardo, et al.
Publicado: (2023)

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
por: Viglietta, Vissia, et al.
Publicado: (2015)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
por: Narapureddy, Bhavya, et al.
Publicado: (2019)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
por: Amezcua, Lilyana, et al.
Publicado: (2023)

Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
por: Kryst, Joanna, et al.
Publicado: (2020)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
por: Cunill, Vanesa, et al.
Publicado: (2018)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
por: Allan, Michelle, et al.
Publicado: (2019)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
por: Comi, Giancarlo, et al.
Publicado: (2023)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
por: Gold, Ralf, et al.
Publicado: (2021)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate
por: Gül, Sedat, et al.
Publicado: (2023)

A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
por: Saida, Takahiko, et al.
Publicado: (2019)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”
Publicado: (2020)

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
por: Fox, Robert J., et al.
Publicado: (2017)

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
por: Gold, Ralf, et al.
Publicado: (2018)

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC
por: Berger, T, et al.
Publicado: (2019)

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
por: Alroughani, Raed, et al.
Publicado: (2017)

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
por: Naismith, Robert T., et al.
Publicado: (2020)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2tjio6f3r4j04lqor56eapklr